论文部分内容阅读
目的 研究血小板激活因子拮抗剂ＢＮ５２０２１对大鼠缺血再灌注损伤肝脏的影响。方法 将大鼠分成３组，对照组未行缺血及药物治疗，缺血再灌注损伤组，ＢＮ５２０２１治疗组，比较各组血清谷丙转氨酶（ＡＬＴ）、谷草转氨酶（ＡＳＴ）、碱性磷酸酶（ＡＫＰ）、γ－ＧＴ等各项指标，肝脏的细胞能荷。结果 用血小板激活因子拮抗剂治疗组血清ＡＬＫ、ＡＳＴＩ、ＡＫＰ、γ－ＧＴ均较缺血再灌注损伤组显著降低，能荷水平明显升高。结论 表明ＢＮ５２０２１用于大鼠肝脏缺血再灌注治疗可减少肝脏的损害，提示血小板激活因子（ＰＡＹ）对肝脏缺血再灌注损伤的发生起一定作用，ＢＮ５２０２１有可能用于肝脏缺血再灌注损伤的治疗。
Objective To study the effect of platelet activating factor antagonist BN52021 on the hepatic ischemia-reperfusion injury in rats. Methods The rats were divided into three groups. The rats in the control group were not subjected to ischemia and drug treatment, ischemia / reperfusion injury group and BN52021 treatment group. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AKP), γ-GT and other indicators, the liver cells can charge. Results Serum levels of ALK, ASTI, AKP and γ-GT in the treatment with platelet-activating factor antagonist were significantly lower than those in ischemia-reperfusion injury group, and their energy levels were significantly increased. The results showed that BN52021 was used in rat liver ischemia reperfusion therapy can reduce liver damage, suggesting that platelet activating factor (PAY) play a role in the occurrence of hepatic ischemia-reperfusion injury, BN52021 may be used for liver ischemia-reperfusion injury Treatment.